<div class="container">

<table style="width: 100%;"><tr>
<td>pancreatic2</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>pancreatic2

</h2>

<h3>Description</h3>

<p>This is the same data as in 'pancreatic', with overall and progression-free survival calculated. Dates have been removed.
</p>


<h3>Usage</h3>

<pre><code class="language-R">data("pancreatic2")</code></pre>


<h3>Format</h3>

<p>A data frame with 41 observations on the following 4 variables.
</p>

<dl>
<dt><code>pfs</code></dt>
<dd>
<p>Progression-free survival: Time from entry until disease progression. 
If no progression was observed, before death, the time to death is used.</p>
</dd>
<dt><code>os</code></dt>
<dd>
<p>Overall survival: Time from entry until death</p>
</dd>
<dt><code>status</code></dt>
<dd>
<p>This censoring indicator is 1 for all patients, since all patients died.</p>
</dd>
<dt><code>stage</code></dt>
<dd>
<p>a factor with levels <code>LA</code> (locally advanced) or <code>M</code> (metastatic)</p>
</dd>
</dl>
<h3>References</h3>

<p>Moss RA, Moore D, Mulcahy MF, Nahum K, Saraiya B, Eddy S, Kleber M, and Poplin EA (2012)
A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer. Gastrointestinal Cancer Research 5, 77 - 83.
</p>


<h3>Examples</h3>

<pre><code class="language-R">data(pancreatic2)

</code></pre>


</div>